跳至主要内容
临床试验/EUCTR2017-000421-13-NL
EUCTR2017-000421-13-NL进行中(未招募)1 期

ewborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxideversus intravenous Sildenafil:an international randomized controlled trial - CoDiNOS trial

Erasmus MC0 个研究点目标入组 90 人开始时间: 2017年6月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Erasmus MC
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diagnosis of CDH and pulmonary hypertension defined as 2 of the
  • following 4 criteria:
  • I. PAP> 2/3 systemic pressure estimated by echocardiography
  • II. RV dilatation/septal displacement, RV dysfunction +/- LV
  • dysfunction
  • III. Pre-post ductal SpO2 difference > 10%
  • IV. OI>20.
  • Parental informed consent
  • Children born at or after a gestational age of 34 weeks
  • Newborns who received a fetal intervention may be included
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 90
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Severe chromosomal anomaly, like trisomy 18 or trisomy 13, which
  • may imply a decision to stop or not to start life-saving medical treatment
  • Severe cardiac anomaly, expected to need corrective surgery in the
  • first 60 days of life (such as transposition of the great arteries, truncus
  • arteriosus, coarctation aortae or double outlet right ventricle)
  • Renal anomalies associated with oligohydramnios
  • Severe orthopaedic and skeletal deformities, which are likely to
  • influence thoracic, and / or lung development (such as chest wall
  • deformities and spine anomalies)
  • Severe anomalies of the central nervous system

研究者

发起方
Erasmus MC

相似试验